The product
A compounded, rapid-dissolving sublingual tablet combining sildenafil and tadalafil. Two of the four ingredients found in the more aggressive stacks, which makes it the most conservative combination product of the five — though combining two PDE5 inhibitors at all is still not something any guideline supports.
The doses are not published. Given that the whole point of a sublingual is faster absorption, and that absorption route changes how much drug reaches the bloodstream, that is information a reader is entitled to.
What it discloses, and what it does not
To its credit, the page states plainly: “Compounded medication. Not FDA-approved.” That is the disclosure MEDVi omits entirely, and it is the single most important piece of context for this whole product category.
But the nitrate interaction is absent from the page, as is the four-hour erection rule, as is any cardiac warning. Side effects sit behind an Important Safety Information link rather than in front of the reader at the point of decision.
That is legally orthodox and practically weak. Almost nobody clicks the safety link. For a company of this size, the gap between what it could disclose and what it chooses to put on the page is the most notable thing about this review.
The price to watch
$28 is a first-order price. The regular figure shown is $48, and the page describes a recurring plan. Budget on $48, not $28 — and note that cancellation terms are not on the page.
At $48 a month you are paying a substantial premium over generic sildenafil, which can be a couple of dollars a dose. What you buy for the difference is convenience and the dissolving format, not better medicine.
The bottom line
A credible company selling a compounded stack behind a page that under-informs. If you use it, read the Important Safety Information link before your first dose rather than after — and tell them about every heart medication you take, because this page will not think to ask. What a good intake should ask you.